Avacta Group (LON:AVCT) Hits New 12-Month High – Time to Buy?

Shares of Avacta Group Plc (LON:AVCT) reached a new 52-week high during trading on Thursday . The company traded as high as GBX 75 and last traded at GBX 72.05, with a volume of 2528796 shares. The stock had previously closed at GBX 71.90.

Analyst Upgrades and Downgrades

Separately, Peel Hunt restated a “buy” rating and issued a GBX 99 price target on shares of Avacta Group in a research note on Monday, October 13th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of GBX 99.

Avacta Group Trading Down 1.5%

The business has a fifty day simple moving average of GBX 62.47 and a 200-day simple moving average of GBX 46.17. The company has a debt-to-equity ratio of 52.53, a quick ratio of 4.96 and a current ratio of 1.29. The firm has a market cap of £293.66 million, a price-to-earnings ratio of -4.10 and a beta of 1.12.

Avacta Group (LON:AVCT) last announced its quarterly earnings results on Tuesday, September 30th. The biotechnology company reported GBX (4.46) EPS for the quarter. Avacta Group had a negative net margin of 114.45% and a negative return on equity of 74.00%. As a group, equities analysts forecast that Avacta Group Plc will post -9.9011833 earnings per share for the current fiscal year.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).